Company Profile
Sensus Healthcare, Inc. is a US-based manufacturer of superficial radiation therapy systems, headquartered in Boca Raton, Florida, United States. Founded in 2010 by Kalman Fishman, the company operates as an independent publicly traded entity on NASDAQ (SRTS), serving dermatology practices, radiation oncologists and healthcare providers worldwide. The company's systems have treated more than 400,000 patients globally. In 2026, the company launched Sensus Healthcare Financial Services to support customer acquisition and financing flexibility.
Core Products ＆ Technologies
Superficial Radiation Therapy Systems
• SRT-100™: A photon x-ray low-energy superficial radiotherapy system providing a non-surgical alternative for treating non-melanoma skin cancers and keloids
• SRT-100+™: An enhanced next-generation SRT system with expanded energy range, remote diagnostics, new X-ray tube, advanced console and EMR integration, cleared by FDA in September 2024
• SRT-100 Vision™: The only FDA-cleared image-guided superficial radiation therapy system, integrating high-frequency ultrasound, volumetric tumor analysis and real-time treatment planning
Software ＆ Services
• Sensus Link: A software platform providing enhanced workflow, treatment documentation and operating intelligence capabilities to the SRT-100 installed base
• Sensus Healthcare Financial Services: Customer financing solutions launched in 2026 to support system acquisition and flexible payment options
Market Position ＆ Certifications
Sensus Healthcare holds a specialized leadership position in the global superficial radiation therapy market for dermatology, competing with Xoft (iCAD) and Elekta. Key strengths include:
• 15+ years of US engineering heritage in non-invasive skin cancer treatment
• Clinical outcomes: 98.7%+ non-recurrence rate for non-melanoma skin cancer; 94%+ cure rate for keloids
• Regulatory compliance: FDA-cleared for non-melanoma skin cancer and keloid treatment
• Recurring revenue growth: Fair Deal Agreement program and Sensus Link expanding utilization-based revenue streams
• Global patient impact: More than 400,000 patients treated worldwide
Corporate Timeline
2010 — Founded by Kalman Fishman in Boca Raton, Florida
2016 — Initial Public Offering on the Nasdaq stock exchange (SRTS)
2024 — FDA 510(k) clearance for the SRT-100+ next-generation superficial radiation therapy system
2026 — Dedicated CPT codes for SRT and IG-SRT take effect; Sensus Link software platform introduced
Target Markets ＆ Applications
• Non-Melanoma Skin Cancer: SRT-100, SRT-100+ and SRT-100 Vision for basal cell and squamous cell carcinoma treatment in dermatology and oncology clinics
• Keloid Management: Post-surgical and standalone SRT treatment for keloid scar prevention and reduction
• Image-Guided Dermatological Care: SRT-100 Vision for precision treatment planning with integrated ultrasound visualization
Contact Information
Global Headquarters
Address: 851 Broken Sound Parkway NW, Suite 215, Boca Raton, Florida 33487, United States
Investor Relations
Stock: NASDAQ: SRTS
Website: sensushealthcare.com
Investor Relations: sensushealthcare.com/investors/
